Partners
DIAMOND PARTNER
For more information, please visit www.otsuka-us.com.
PLATINUM PARTNERS
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.
Our medicines reached 296 million people worldwide.
For more information, please visit www.novartis.com.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.
For more information, please visit www.roche.com, Linked in, Facebook, X, Instagram, YouTube
STADA Specialty Care is a leading provider of innovative medicines across indications including nephrology, CNS and immunology. This portfolio includes the first medicine approved in the EU and the UK for treating the rare kidney disease IgA-Nephropathy (IgAN) as well as an epoetin zeta biosimilar. Other marketed biosimilars cover dermatology, gastroenterology, oncology, osteoporosis and ophthalmology indications, while the group also offers a range of Parkinson’s disease therapies.
Such Specialty medicines account for 21% of STADA's 2024 group revenues that increased by 9% to EUR 4.1 billion. As Europe's fourth-largest supplier by value of generic medicines and consumer healthcare products, Germany-based STADA markets its products more than 100 countries worldwide.
For more information, please visit www.stada.de.
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis.
For more information, please visit www.veratx.com.
BRONZE PARTNERS
Reliant Glycosciences, LLC is a biotechnology company dedicated to developing diagnostic and prognostic tools for patients with IgA nephropathy (IgAN). The company's objective is to create marketable assays for IgAN-specific biomarkers, making them accessible to both the IgAN research community and pharmaceutical companies interested in developing treatments for this condition.
Reliant offers its own GalD Assay, which measures the level of galactose-deficient IgA1 (Gd-IgA1) in human serum samples. This assay is quantitatively assessed using a lectinbased ELISA test. Reliant aims to make a meaningful impact on the disease and its treatment.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.
For more information, please visit www.takeda.com.
